In vivo suppression of polyglutamine aggregation via co-condensation of the molecular chaperone DNAJB6
E. Preusser de Mattos, M. Kolbe Musskopf, S. Bergink, H. H. Kampinga
Abstract
Amyloidogenic protein aggregation is a hallmark of several human neurodegenerative conditions, including Alzheimers, Parkinsons, and Huntingtons disease (HD). Mutations and/or environmental stresses trigger conformational transition of specific proteins to amyloids, conferring them with gain of toxic function, which eventually leads to cell death in distinct brain areas. Cumulative data indicate that modulation of specific molecular chaperones can alleviate many of the pathological features of protein aggregation diseases. We previously showed that the Hsp70 co-chaperone DNAJB6 is among the strongest suppressors of amyloid aggregation, and that moderate DNAJB6 overexpression significantly extents lifespan of a mouse model of aggressive HD pathology. DNAJB6 alone delays amyloidogenic aggregation in vitro by several orders of magnitude at substoichiometric ratios, but its activity in cells is less efficient, albeit still markedly superior to most known anti-amyloidogenic agents. This suggests that downstream PQC factors are necessary for full DNAJB6-mediated suppression of aggregation in vivo, which might have to be co-stimulated in therapeutic strategies targeting DNAJB6 action. We explored here the PQC pathways required for optimal DNAJB6 inhibition of polyglutamine (polyQ) aggregation, focusing on the two main cellular proteolytic machineries: proteasomes and macroautophagy. Unexpectedly, DNAJB6 activity was largely insensitive to chemical blockage of either degradative pathway. Instead, live cell imaging unveiled a co-condensation mechanism of DNAJB6 with mobile polyQ assemblies. DNAJB6 was not required for polyQ condensation, but its expression increased the percentage of cells with mobile condensates by a factor of 3, suggesting that DNAJB6 prevents polyQ condensates to convert from the soluble to the solid state. This in turn, may keep the polyQ peptides competent for (regulated) degradation and accessible to factors allowing its extraction from the condensed state.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A two-bead-per-aminoacid coarse-grained MD model with hydrogen bonding (2BPA-HB) to probe DNAJB6b-mediated suppression of polyglutamine aggregation in Huntingtons disease
Vasista Adupa, Johan David Polet, … Patrick R. Onck·bioRxiv·Aug 27, 2026
- The Hsp40 co-chaperone DNAJC7 regulates polyglutamine aggregation and exhibits context-dependent effects on polyglycine aggregation
Biswarathan Ramani, Kean Ehsani, Martin Kampmann·Journal of Biological ChemistryPeer-reviewed·Feb 17, 2026
- DNAJB chaperones inhibit aggregation of destabilised proteins via a C-terminal region distinct from that used to prevent amyloid formation
S. McMahon, S. Bergink, … H. Ecroyd·bioRxiv·Oct 8, 2020
- DNAJB6b: a complete amyloid inhibitor
Andreas Carlsson, Ulf Olsson, Sara Snogerup Linse·bioRxiv·Sep 7, 2026
- Amyloid-β oligomers are captured by the DNAJB6 chaperone: Direct detection of interactions that can prevent primary nucleation
N. Österlund, M. Lundqvist, … C. Emanuelsson·bioRxiv·Mar 16, 2020
- Chaperone AMPylation modulates aggregation and toxicity of neurodegenerative disease-associated polypeptides
M. C. Truttmann, D. Pincus, H. L. Ploegh·bioRxiv·Sep 1, 2017